Company intelligence / Profile preview
Band Therapeutics LLC
Lexington, Massachusetts, United Statesguardiantherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Band Therapeutics has completed a Phase 1 program for BT200 (NCT04103034) in Q4 2020 and initiated a Phase 2 pilot study in hereditary bleeding disorders (NCT04677803) in Q1 2021. Their lead candidate Rondaptivon Pegol is currently in Phase 3 for Von Willebrand Disease, Type 2.
- Therapeutic areas
- Hematology
- Modalities
- AptamersSmall molecule drug
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on Band Therapeutics LLC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Band Therapeutics LLC.